SCHEMBL2403486

SCHEMBL2403486

O=C1Cc2cc3c(CCC4CCN(Cc5cccc(Br)c5)CC4)noc3cc2N1

nearest known ligand 0.82

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ACHE P22303 20/20 0.82
BCHE P06276 7/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2405514 0.91 ACHE (0.84) ACHEBCHE
Icopezil SCHEMBL194482 0.91 ACHE (1.00) ACHEBCHE
SCHEMBL4512593 0.87 ACHE (1.00) ACHEBCHE
SCHEMBL2402320 0.85 ACHE (0.90) ACHEBCHE
Icopezil SCHEMBL2231222 0.85 ACHE (1.00) ACHEBCHE
Icopezil SCHEMBL3339253 0.85 ACHE (1.00) ACHEBCHE
SCHEMBL8574448 0.84 ACHE (0.59) ACHEBCHE
SCHEMBL27340198 0.84 ACHE (0.59) ACHEBCHE
SCHEMBL220485 0.83 ACHE (1.00) ACHEBCHE
Icopezil SCHEMBL9276199 0.82 ACHE (0.93) ACHEBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951873-B1 Methods for treating age-related behavioral disorders in companion animals PFIZER INC. (US) 2005-10-04 US claimed
EP-1050303-A2 Methods and compositions for treating age-related behavioral disorders in companion animals Pfizer Products Inc. (US) 2000-11-08 EP claimed
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2022-08-25 US disclosed
US-11160785-B2 Methods and compositions for improving cognitive function AGENEBIO INC. (US) 2021-11-02 US disclosed
US-20180015109-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2018-01-18 US disclosed
US-20160271108-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION AGENEBIO, INC. 2016-09-22 US disclosed
EP-2533645-B1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2016-07-27 EP disclosed
US-20110212928-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2011-09-01 US disclosed
US-6951873-B1 Methods for treating age-related behavioral disorders in companion animals PFIZER INC. (US) 2005-10-04 US disclosed
US-6498255-B2 CHOLINESTERASE INHIBITORS; COGNITION ACTIVATORS; ALZHEIMER'S DISEASE; E.G., 3-(2-(1-(PHENYLMETHYL)-4-PIPERIDINYL)ETHYL)-1,2-BENZISOXAZOLE PFIZER INC. 2002-12-24 US disclosed
EP-1050303-A2 Methods and compositions for treating age-related behavioral disorders in companion animals Pfizer Products Inc. (US) 2000-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160271108-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, BACE1, GRIN2A ACHE 4/4885BCHE 29/4885
US-11160785-B2 Methods and compositions for improving cognitive function BACE2, BACE1, GRIN2A ACHE 4/4885BCHE 29/4885
US-20180015109-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE ACHE 3/4885BCHE 47/4885
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE ACHE 3/4885BCHE 47/4885
US-20110212928-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE ACHE 3/4885BCHE 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.